Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotinib + Gemcitabine in Pancreatic Cancer
NCT02278458Phase 1Unknown
- Sponsor
- Betta Pharmaceuticals
- Start
- Oct 2014
- Primary completion
- Jan 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of icotinib in pancreatic cancer (PC), sponsored by Betta Pharmaceuticals. Primary endpoint: Number of patients who suffer adverse events at 24 months. Status: unknown.
02
Drugs
icotinib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02278458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02278458.